Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 67 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Apr 1, 2026, no change to tracked fieldsv66-v67
  2. Primary and study completion dates: May 2026 to May 2027v65
  3. Re-verified, no change to tracked fieldsv64
  4. Eligibility criteria shortened, about 2 wordsv63
  5. Re-verified, no change to tracked fieldsv62
Show 44 earlier versionsHide 44 earlier versions
  1. Site contact updatedv61
  2. Re-verified, no change to tracked fieldsv60
  3. Primary and study completion dates: May 2025 to May 2026
    • Eligibility criteria expanded, about 17 words
    v59
  4. Site contact updatedv58
  5. Interventions: iobenguane I 131 (Radiation) to iobenguane I 131 (Drug)
    • Site contact updated
    v57
  6. 2 versions Re-verified since Mar 8, 2024, no change to tracked fieldsv55-v56
  7. Primary and study completion dates: May 2023 to May 2025v54
  8. 3 versions Re-verified since Apr 26, 2022, no change to tracked fieldsv51-v53
  9. Site contact updatedv50
  10. Enrollment target: 150 to 200v49
  11. Primary and study completion dates: May 2022 to May 2023v48
  12. Primary and study completion dates: May 2021 to May 2022v47
  13. Primary and study completion dates: May 2020 to May 2021v46
  14. Primary and study completion dates: May 2019 to May 2020v45
  15. Enrollment target: 80 to 150v44
  16. Primary and study completion dates: May 2018 to May 2019v43
  17. Primary and study completion dates: May 2017 to May 2018v42
  18. Study description shortened, about 190 words
    • Site contact updated
    v41
  19. Primary and study completion dates: May 2016 to May 2017v40
  20. 2 versions Re-verified since Jul 21, 2015, no change to tracked fieldsv38-v39
  21. Primary and study completion dates: May 2015 to May 2016
    • Eligibility criteria expanded, about 122 words
    • Study site revised
    v37
  22. Re-verified, no change to tracked fieldsv36
  23. Primary and study completion dates: May 2014 to May 2015v35
  24. 2 versions Re-verified since Jul 31, 2013, no change to tracked fieldsv33-v34
  25. Primary and study completion dates: May 2013 to May 2014v32
  26. Enrollment target: 38 to 80v31 Show 7 more changesShow less
    • Primary completion date: Jan 2010 to May 2013
    • Study completion date: May 2013
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description shortened, about 29 words
    • Site contact updated
    • Study arms: 0 to 1
    • Collaborators expanded, about 4 words
  27. Study description revisedv30
  28. Study description expanded, about 20 wordsv29
  29. 2 versions Re-verified since Jul 7, 2009, no change to tracked fieldsv27-v28
  30. Interventions: arsenic trioxide (Drug), iodine I 131 metaiodobenzylguanidine (Radiation) to iobenguane I 131 (Radiation)
    • Study description shortened, about 10 words
    • Study title shortened, about 3 words
    v26
  31. Site details revisedv25
  32. Interventions: arsenic trioxide (Drug), iodine I 131 metaiodobenzylguanidine (Drug) to arsenic trioxide (Drug), iodine I 131 metaiodobenzylguanidine (Radiation)v24
  33. Re-verified, no change to tracked fieldsv23
  34. Start date: Jan 2005 to May 2006v22
  35. 2 versions Re-verified since Jul 23, 2008, no change to tracked fieldsv20-v21
  36. Study Status, Contacts/Locationsv19
  37. Interventions: arsenic trioxide (Drug), chemotherapy (Procedure), iodine I 131 metaiodobenzylguanidine (Drug), radioisotope therapy (Procedure)… to arsenic trioxide (Drug), iodine I 131 metaiodobenzylguanidine (Drug)v18
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Trial Details
NCT Number NCT00107289
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Neuroblastoma, Pheochromocytoma
Related terms Neuroblastoma, Pheochromocytoma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov